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Abstract
Objective. Pressure injuries (PI) are largely preventable and can be viewed as an adverse outcome of a healthcare
admission, yet they affect millions of people and consume billions of dollars in healthcare spending. The existing literature
in Australia presents a patchy picture of the economic burden of PI on society and the health system. The aim of the present
study was to provide a more comprehensive and updated picture of PI by state and severity using publicly available data.
Methods. A cost-of-illness analysis was conducted using a prevalence approach and a 1-year time horizon based on
data from the existing literature extrapolated using simulation methods to estimate the costs by PI severity and state
subgroups.
Results. The treatment cost across all states and severity in 2012–13 was estimated to be A$983million per annum,
representing approximately 1.9% of all public hospital expenditure or 0.6% of the public recurrent health expenditure. The
opportunity cost was valued at an additional A$820million per annum. These estimates were associated with a total number
of 121 645 PI cases in 2012–13 and a total number of 524 661 bed days lost.
Conclusions. The costs estimated in the present study highlight the economic waste for the Australian health
system associated with a largely avoidable injury. Wastage can also be reduced by preventing moderate injuries (Stage
I and II) fromdeveloping into severe cases (Stage III and IV), because the severe cases, accounting for 12%of cases,mounted
to 30% of the total cost.
What isknownabout the topic? The literature has identiﬁed that in theAustralianhealth care system,woundmanagement
is one of themost frequently performed procedures. However, the overall economic cost of PI to the public hospital system is
largely unknown.
Whatdoes this paper add? This study provides reliable estimates, based predominantly onAustralian data, of the number
of cases and treatment costs associatedwithPI inpublic hospitals, disaggregatedby state and severity.Thepaper also attempts
to quantify the opportunity cost of PI, which leads to extra hospital length of stay. The estimated costs give an indication of
the economic waste to the health system due to avoidable injury.
Whatare the implications forpractitioners? This study is relevant and important in the context of rising healthcare costs.
It highlights anarea for potential improvement inqualityof care (i.e. better hospital experience forpatients) andefﬁciency (i.e.
reducing economic waste) in the hospital sector. It also reveals the paucity of data available to support cost estimation, from
theprevalence and incidence rates to the treatment cost bydisease severity,which further highlights anunder-researched area.
Additional keywords: opportunity cost, pressure ulcer, prevalence rate, treatment cost.
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Introduction
Pressure injury (PI) is considered one of themost common causes
of iatrogenic harm to patients.1 It is associated with sustained
pain, discomfort and increased immobility and mortality rates in
addition to decreased quality of life in both acute and long-term
care settings.2,3 It also carries a substantial ﬁnancial burden
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associated with ongoing care incurred by individuals and
families, the healthcare system and society. As a preventable
condition, PI prevalence is being measured nationally and
internationally as an indicator of quality of nursing care in
health facilities, and complainants in litigation can be awarded
substantial costs.4–6 In Australia, The National Safety and
Quality Health Service Standards provide health service leaders
guidance on areas to target in improvement strategies. Standard
8, Preventing and Managing Pressure Injury, requires health
service organisations to implement evidence-based systems to
prevent PIs and to manage them when they do occur.7 Yet,
hospital-acquired PI remains an unsolved problem.
The treatment for PIs is known to be costly; however, there
is little precise information on prevalence and costs.8 The prev-
alence rate, and subsequently estimated number of PI cases,
varies signiﬁcantly from one study to the next. Studies have
reported prevalence rate estimates ranging from 2 to 23%2,9–17
and incidence rates between 1.5 and 38%.18–22 In Australia, the
overall reported PI prevalence between 1983 and 2002 ranged
between 3 and 36.7%.23 The variation is associated with health-
care setting (acute care vs long-term care vs home care), disease
speciﬁc (e.g. spinal cord injury, cardiovascular etc.) and data
collection methods (e.g. hospital surveys, patient-level data).34
More speciﬁcally, state-wide audits estimate PI prevalence in
hospitals ranges from 9.5 to 17.6%.10 Studies in nursing home
and long-term care settings estimate the prevalence of PI to be
around 8.9%.25,26
Similarly, studies investigating the ﬁnancial burden
associated with PIs have presented a wide range of estimates
along several dimensions, such as degree of severity (Stage I to
IV),27 additional length of stay (LOS) attributable to PIs and
whether PIs occurred in medical or surgical patients.16,19,22,28
The variation in cost per case is substantial, with estimates
ranging between US$500 and US$40 000 in the US9,29 and
from £1214 for Stage I to £14 108 for Stage IV in the UK.17
Findings suggest that personnel costs, such as nursing and carers’
time, contribute a large proportion of the total treatment cost,
whereas the use of medical materials, special beds andmattresses
only make a minor contribution.30 For severe cases, complica-
tions that lead to delayed healing, additional diagnostic tests
and monitoring and extended LOS are a major determinant of
cost.16 Subsequently, there is a wide range of cost estimates
associated with PI treatment across countries (from millions
to billions of dollars),2,8,9,16,30,31 representing between 0.4 and
6.6% of a country’s health expenditure.
There have been studies on the prevalence and economic
losses of PI in Australia. Graves et al. estimated the impact of
PI on in-patient LOS, as well as the opportunity cost of bed days
lost using 2001–02 data.19,32 Jackson et al.33 reported that
PI ranked among the top ﬁve hospital-acquired complications
(by total additional system cost). Based on data from 2005–06
(Victoria) and 2006–07 (Queensland), Jackson et al. reported
the total number of PI cases to be 2873, representing a prevalence
of 0.2% (much lower than the prevalence estimated in other
studies1,34,35) and a total cost of A$22.9million for the public
hospitals in these two states.33 It is noted that this prevalence
rate, and thus estimated cost, was likely to be underestimated.
Jackson et al.33 derived the estimates from data collected retro-
spectively using the Diagnosis-Related Group (DRG) system,
whereas the state reports1,34,35 estimated their prevalence rates
from prospective prevalence surveys where PI was recorded
through direct skin inspection, which was more likely to be
more accurate. Antonio and Conrad36 presented an evaluation
of the Wound Care Improvement program in the Ballarat
Health Service (Victoria), in which prevalence data by PI stage
were collected for 2009, 2011and2012.That study also estimated
cost saving attributable to the reduction of PI; however, the
sample was small and not representative of Victoria or wider
Australia. The most recent study, by Graves and Zheng,37 esti-
mated the direct healthcare costs of chronic wounds in Australia
to be A$1.13 billion (0.72 billion) for the 2010–11
ﬁnancial year. None of these studies estimated the costs disag-
gregated by PI stage.
The states of Victoria, Queensland, Western Australia and
South Australia have conducted regular PI audits and introduced
hospital-acquired PI as a quality control indicator, rationalising
that PI is largely preventable in the hospital setting if appropriate
and timely screening, skin assessment and prevention strategies
are applied. These efforts have generated some data on PI
for Australian public facilities.1,10,34,35,38–40 Yet, the annual PI
cost to the public hospital systemand,more broadly, toAustralian
society, as well as the impact of PI severity on costs, remain
largely unknown.
In the present study, we investigate the direct treatment
cost related to PI, as well as the indirect opportunity cost of
bed days lost due to preventable PIs, by PI severity andAustralian
states and territories, in the context of public hospitals. We retain
our focus on the costs of treatment, and do not estimate the cost
of prevention, which has been the focus of cost-effectiveness
studies.41,42
Methods
A cost-of-illness analysis was conducted using a prevalence
approach and a 1-year time horizon, based on data from the
existing literature extrapolated using simulation methods. The PI
treatment cost was estimated in the public hospital setting,
disaggregated by stage (from Stage I to IV)7 and by state and
territory. This cost was a direct health system cost that included
nursing time for risk assessment, monitoring and repositioning,
skin dressings, moisturiser, antibiotics and analgesics and sup-
porting surfaces. The indirect opportunity costs associated with
extended LOS represented the value that should have been
produced (in terms of the value of beneﬁts for patients with other
illness who could have been treated) if PI were to be completely
prevented. This cost was disaggregated by state and territory.
The direct and indirect costs were then summed to give an overall
estimate of the costs to the Australian public hospital system and
society more broadly.
Direct treatment cost
We used existing data from the published and grey literature to
estimate: (1) the number of patients with PIs, by stage and
state; (2) the average treatment cost for each PI stage; and
(3) the total treatment cost, by stage and by state.
Number of patients with PI cases
The estimation of PI cases was based on the number of in-
patient cases at risk of PI and the prevalence rate. A wide range
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of prevalence rates has been reported in Australia, from as low
as 0.2% in the study of Jackson et al.33 to 17.6% in the Western
AustraliaWound Prevalence Survey.10 To incorporate uncertain-
ty around the true prevalence, we ﬁtted a beta distribution, which
is suitable for parameters bounded by 0 and 1, using theminimum
(0.2%) and maximum (17.6%) values reported in the Australian
literature.1,7,32–34,38,39 The number of cases with PI was then
calculated as the product of the estimated prevalence rate and the
number of in-patient cases (discharges), sourced fromAustralian
hospital statistics 2012–13.43
Average treatment cost of each PI stage
We used the average treatment cost per case by stage (from
Stage I to IV) estimated in aUKstudy byDealey et al.16Although
data derived fromAustraliawould be preferred, to our knowledge
these data are not available. Jackson et al.33 only provide the
average cost per case, not disaggregated by stage, whereas
Graves and Zheng37 used estimated cost per case from the
international literature. The system of PI staging in the UK is
comparable to that used inAustralia, as deﬁned by the Pan Paciﬁc
Clinical Practice Guidelines.27 In addition, the translation of
costs related to use of dressings, medication, equipment and
nursing time for the management of PIs is considered to be a
reasonable approximation, given the similarities in theAustralian
and UK public health systems.
The treatment cost in Dealey et al.32 was estimated by the
bottom-up costing method using 2011 data. It took into account
daily resources for PI treatment, such as nursing time, special
mattresses, dressings and medication. The marginal cost of
bed day (£300) was included only for PI associated with cellulitis
and osteomyelitis. To avoid double counting the bed day cost
(which was included in the estimation of opportunity cost PI
discussed below), we removed it from the treatment cost per case.
All costs in UK 2011 prices were converted to Australian
2012–13 prices using the web tool by Shemilt et al.44 (see
Table 1). The stage-speciﬁc cost per case was generated from
a uniform distribution with the minimum and maximum values
speciﬁed as 10% of the average cost per stage.
Total treatment cost
Total treatment cost was calculated as the product of the
number of PI cases and the cost per case, and disaggregated
by PI stage (using shares of PI cases by severity) and state (using
number of discharges). The associated standard deviations were
computed from a simulated sample generated by a mixed distri-
bution of beta (the number of PI cases) and uniform (treatment
cost per case) distributions.
Indirect opportunity cost
From a societal perspective, the indirect opportunity cost of
PI is represented in part as the costs associated with bed days
lost due to preventable cases. That is, if PI is completely pre-
vented, there would be more bed days available for treatment
of other illness. In the literature, this value is approximated
by ‘willingness to pay’ for those bed days.32 Other societal costs,
such as those related to lost productivity for carers or the
intangible cost arising from reduced quality of life, were not
included due to a lack of data thatwould support their valuation.45
The calculation of the opportunity cost associated with
lost bed days due to PI involved: (1) identifying the number of
bed days wasted due to PI (extended LOS); (2) calculating
average opportunity cost per bed day; and (3) estimating the total
opportunity cost of extended bed days.
Additional bed days
The independent effect of PI on LOS estimated by Graves
et al.31 was used in the analysis. The mean ( s.d.) estimate of
4.31 ( 1.26) days for additional LOS was used to specify the
gamma distribution parameters (a and b) for the simulation.
The disaggregation of LOS by PI stage was based on Dealey
et al.16 due to a lack of data from Australian studies. This choice
ensures consistency because treatment cost per case by stage was
also sourced from the same study.
Average opportunity cost per bed day
In the Australian public hospital context, the opportunity
cost (or willingness to pay) for a bed day can be approximated
by the average casemix-adjusted cost per bed day. The average
cost per overnight discharge for each state of Australia was
extracted from the Australian Hospital Statistic collection
2012–13.43 Overnight discharge cost is used because PI is
associated with extended LOS.
Total opportunity cost of extended bed days
The total value of bed days lost due to PIs for each PI stage
was then calculated as the product of the number of bed days lost
and average cost per bed day. The former was estimated from
the number of PI cases and the average extended LOS per case.
Table 1. Treatment cost per case, by pressure injury stage and health state and mean cost per patients
Data were sourced from Dealey et al.16 Costs in A$ were calculated using the web-based tool developed by Shemilt et al.44 PI, pressure injury
Normal
healing (£)
With critical
colonisation (£)
With
cellulitis (£)
With
osteomyelitis (£)
Mean cost
(£) 2011
Mean cost
(A$) 2013
Stage 1 (28 days) 1196.44 1196.44 2746.85
Probabilities 100%
Stage 2 (92 days) 4314.80 5726.08 6647.92 6846.64 4506.99 10 347.40
Probabilities 90% 5% 2.5% 2.5%
Stage 3 (127 days) 7209.79 8978.90 9177.02 9451.34 7597.14 17 441.93
Probabilities 80% 10% 5% 5%
Stage 4 (155 days) 8799.35 10 958.50 11 200.30 11 535.10 9785.77 22 466.71
Probabilities 60% 10% 15% 15%
Mean cost of PI (weighted average) 3708.12 8513.30
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Because the extended LOS was generated from a gamma distri-
bution and the number of PI cases was generated from a beta
distribution, the opportunity cost, as the product of extended
LOS, PI case and cost per bed days, was generated from a mixed
distribution.
The variables and assumptions underlying the estimation
process are summarised in Table 2. We obtained point estimates
and conﬁdence intervals (CI) for the prevalence rates, LOS and
treatment costs using appropriate probability distributions under
the Monte Carlo simulation with 10 000 draws. Stata 13 (Stata-
Corp, College Station, TX, USA) was used for all estimations.
Results
Our estimates suggest that the prevalent number of cases of
PI for Australian public hospitals for 2012–13 was 121 645
(95% CI 100 846–142 444). The resulting treatment cost across
all states andPI stageswas estimated tobeA$983million (95%CI
A$815–1151million) per annum, representing approximately
1.9% of all public hospital expenditure (A$42 billion in the
same period)46 or 0.6% of the public recurrent health expenditure
(A$132 billion).46
Tables 3 and 4 give the number of cases and associated
treatment costs disaggregated by state and PI stage. As expected,
the three largest states of New South Wales, Victoria and
Queensland shouldered approximately 75% of the total cases
and cost for Australia. The estimates also indicate that the large
cost burdens came from Stage II and IV (30% of cost), the former
due to its largest share of PI cases and the latter due to its high
treatment cost per case.
The total number of bed days lost for Australia was estimated
at 524 661 (95% CI 366 067–683 254) per annum and the result-
ing opportunity cost was valued at A$819million per annum
(95% CI A$572–1067million). The disaggregation of extra
Table 2. Key variables for the estimations
MDC, major diagnostic category; PI, pressure injury; LOS, length of stay
Variable Assumptions and
calculations
Sources Notes
A No. in-patient
discharges
No. in-patients discharged in public
hospital, assuming that overnight
discharges do not include patients
with PI
Australia Hospital
Statistics 2012/1343
B Overall PI
prevalence rate
Range 0.2%–17.6%; beta distribution
drawn from the prevalence rate
range (sample = 10 000)
Jackson et al.33, Graves et al.32,
States of Victoria, Queensland,
Western Australia pressure ulcer
reports1,10,34,35,38–40
One range of prevalence rate
applied for all states
C Prevalence rates
for individual
PI stages
Prevalence rate for each PI stage =
overall prevalence rate share by
each stage; beta distribution
drawn from the
prevalence rate for each stage
Graves et al.32 for prevalence rate,
Victorian, Queensland, Western
Australian
pressure ulcer reports for
stage share1,10,34,35,38–40
One range of stage-speciﬁc
prevalence rate for all states
D No. PI cases All stages: A (no. discharges)B
(overall prevalence rate)
Calculation from previous
parameters (A, B, C)
By stage: A (no. discharge)
C (stage-speciﬁc
prevalence rate)
E Treatment cost
per case for
each stage
Uniform distribution using ±10% of
the average cost
(per case) for each stage (A$);
costs converted
from British pounds (2011) to
Australian
dollars (2012; see Table 3)
Dealey et al.16,
Shemilt et al.44
Stage-speciﬁc treatment cost
per case is the same for
all states
F Total cost D (no. PI cases)E (treatment
cost per case)
Calculation Total cost for each stage
G Extended LOS Mean (u) = 4.31 bed days; standard
error (s) = 1.26; gamma distribution
with a ¼ u2s2 and b ¼ s
2
u
Graves et al.32 Average extended LOS
(all stages together)
H Opportunity
cost per
bed day
Opportunity cost per bed day is the
‘value per bed day’ that the public
hospital system is willing to pay;
opportunity cost per bed = average
cost per casemix-adjusted
separation/average LOS
Grave et al.32 Opportunity cost per bed day
calculated for each state
I Total opportunity
cost due to bed
days lost
D (no. PI cases)G (extended LOS)
H (opportunity cost per bed day)
Calculation from previous
parameters (D, G, H)
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bed days and opportunity costs by states are presented in
Tables 5 and 6. Again, the greatest numbers of lost bed days
and opportunity cost accrued to New South Wales, Victoria and
Queensland.
The total economic burden of PI to Australia, estimated by
the sum of treatment and opportunity costs, amounted to $1.8
billion per annum, of which 55% was attributable to treatment
cost. Because most PI cases were of Stage I and II (which are
not generally anticipated to extend LOS), the overall estimated
treatment costs were higher than the opportunity costs.
Discussion
The present study provides the most comprehensive estimates of
the economic burden of PI in Australia to date, including the
treatment cost per case by PI stage, total cost of PI treatment by
PI stage and for individual states, and the opportunity cost
associated with bed days lost due to PI. We show that the
estimated overall economic burden of PI for society is substantial.
Although our ﬁndings are generally consistent with the costs
associatedwith PI treatment estimated in the literature, there are a
few major differences between our estimates and those from
comparable Australian studies. Compared with Graves and
Zheng,37 the number of PI cases per annum was smaller in the
present study (121 645 vs 236 295). This was driven by assump-
tions regarding the distribution of the data and the range of
prevalence rates. We used Australian data for the prevalence
rates, whereas Graves and Zheng37 used the rates derived from
the international literature applied to Australian hospital
ﬁgures for the number of discharges. Compared with state audit
reports,10 our prevalence estimates by state were lower, repre-
senting a conservative approach to cost estimation. Our estimate
for the average cost per PI case, based on Dealey et al, (A$8513)
was lower than that reported in Jackson et al. 16 (A$9297), and
higher than that ofGraves andZheng36 (range $A2371–$A7139).
Although Graves and Zheng 36 extracted the average cost per PI
case from the international literature, they did not include the
estimates from Dealey et al. 16 and Jackson et al. 33 This resulted
in lower estimated treatment costs.
The cost estimate presented here is within the range
estimated for other countries. Our estimate of total cost for PI
treatment was lower than other high-income countries, both as
a percentage of public hospital (1.9%) and public recurrent
health expenditure (0.6%). Studies have indicated that treatment
for PI costs range between 0.4 and 3.2% of the UK national
health budget,8,31 1.2% for The Netherlands and 5.2% for
Spain.30 Similarly, various US studies indicate that PI accounts
for approximately 3.9% of in-patient hospital costs per
annum.9,41
Our cost estimate is likely to understate the total burden of
PI for society because we did not include the treatment cost in
long-term and home care settings, or the less tangible costs
associated with quality of life lost and the opportunity cost of
Table 3. Number of pressure injury (PI) cases per annum, by state and PI stage (2012–13)
NSW, New South Wales; Vic., Victoria; Qld, Queensland; WA, Western Australia; SA, South Australia; Tas., Tasmania; ACT, Australia Capitol Territory;
NT, Northern Territory
State Stage I Stage II Stage III Stage IV Total
Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
NSW 16 985 1482 19 769 1725 2465 215 2843 248 42 062 3669
Vic. 11 428 997 13 301 1160 1658 145 1913 167 28 300 2469
Qld 9248 807 10 764 939 1342 117 1548 135 22 901 1998
WA 4998 436 5817 507 725 63 837 73 12 376 1080
SA 4052 353 4717 411 588 51 678 59 10 035 875
Tas. 910 79 1059 92 132 12 152 13 2254 197
ACT 778 68 906 79 113 10 130 11 1928 168
NT 722 63 840 73 105 9 121 11 1788 156
Total 49 120 4285 57 173 4987 7128 622 8223 717 121 645 10 612
Table 4. Total cost of pressure injury (PI) treatment per annum by state and PI stage (2012–13)
NSW, New South Wales; Vic., Victoria; Qld, Queensland; WA, Western Australia; SA, South Australia; Tas., Tasmania; ACT, Australia Capitol Territory;
NT, Northern Territory
Total treatment cost (A$ million)
Stage I Stage II Stage III Stage IV Total
Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
NSW 44.28 3.86 194.17 16.94 40.81 3.56 60.64 5.29 339.90 29.65
Vic. 29.80 2.60 130.64 11.40 27.46 2.40 40.80 3.56 228.69 19.95
Qld 24.11 2.10 105.72 9.22 22.22 1.94 33.02 2.88 185.06 16.14
WA 13.03 1.14 57.13 4.98 12.01 1.05 17.84 1.56 100.01 8.72
SA 10.57 0.92 46.32 4.04 9.74 0.85 14.47 1.26 81.09 7.07
Tas. 2.37 0.21 10.41 0.91 2.19 0.19 3.25 0.28 18.22 1.59
ACT 2.03 0.18 8.90 0.78 1.87 0.16 2.78 0.24 15.58 1.36
NT 1.88 0.16 8.25 0.72 1.73 0.15 2.58 0.22 14.45 1.26
Total 128.07 11.17 561.55 48.99 118.02 10.30 175.36 15.30 983.00 85.75
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PI to patients and families. Nonetheless, our results indicate
that PIs impose a large economic and importantly avoidable
burden to Australia (although, still substantially less than the
top diseases by expenditure). It would be possible to have a
more comprehensive understanding of the economic burden of
this adverse event if better data (e.g. prevalence rates, resources
required for PI treatment and quality of life associated with PI)
were available in both long-term and home care settings.
Although PI is not a completely avoidable adverse event,
some jurisdictions have recently introduced ﬁnancial penalties
to incentivise hospitals to improve quality and avoid hospital-
acquired PIs. Well-known examples include the US implemen-
tation of the hospital-acquired condition reduction program and
the exclusion of certain PI cases considered preventable in the
hospital setting from Medicare payment (since early 2008).47,48
In Australia, Queensland’s activity-based funding model for
2012–13 also includes pressure injury Stage III and IV as adverse
events for which there is a reduced payment for hospitals.49
Because the penalty is designed in the form of a reduction in
government reimbursement to public hospitals, it does not rep-
resent a cost from a health system perspective (although it does
represents a cost from an individual hospital perspective). As
such, these payments are not included in the current analysis. The
extent to which these payments have an impact on improved
quality of care and either the prevalence rates or reported cases of
PI across different stages will become apparent with appropriate
evaluation over the next few years.
The present study has several limitations, most of which relate
to data availability. First, the data were derived from several
different Australian and UK studies, and we assumed these data
are generalisable to the Australian public hospital context. Nev-
ertheless, we incorporated a range of values and distributions
to capture the uncertainty. Second, wemade various assumptions
with regard to the uniformity of prevalence rates, extended LOS
and treatment cost per case across different states of Australia.
Subsequently, there is some degree of uncertainty involved in our
ﬁnal estimations. The total cost estimates fall well within the
range indicated in the international literature.8,9,30,31,41
The present study, together with the paucity of data available
to support cost estimates, highlights an under-researched area.
Further robust data are required to support estimates of the
economic burden associated with this prevalent and costly ad-
verse event and, importantly, comparative evaluation of the cost-
effectiveness of strategies to prevent PIs. For instance, facilities
should develop a systematic collection of PI incidence and
prevalence data to inform health managers on strategic planning,
resource allocation and to track improvement, especially when
hospital-acquiredPI is regarded as a quality indicator (Standard 8,
Preventing andManaging Pressure Injury, of the National Safety
Health Quality Standards is an example42). In the present study,
the impact ofPI on the quality of life of patients, and their families,
has been largely unexplored.However, the estimates available for
time to heal in the literature, with even a Stage I PI estimated to
take on average 28 days to heal,16 suggest the impact on quality of
Table 5. Total number of extra bed days per annum, by state and pressure injury stage (2012–13)
NSW, New South Wales; Vic., Victoria; Qld, Queensland; WA, Western Australia; SA, South Australia; Tas., Tasmania; ACT, Australia Capitol Territory;
NT, Northern Territory
State Stage I Stage II Stage III Stage IV Total
Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
NSW 27 814 8092 109 316 23 297 18 382 3715 25 903 5117 181 416 27 979
Vic. 18 714 5444 73 550 15 675 12 368 2500 17 428 3443 122 060 18 825
Qld 15 144 4406 59 519 12 685 10 008 2023 14 103 2786 98 775 15 233
WA 8184 2381 32 165 6855 5409 1093 7622 1506 53 380 8232
SA 6636 1930 26 080 5558 4386 886 6180 1221 43 282 6675
Tas. 1491 434 5858 1249 985 199 1388 274 9722 1499
ACT 1275 371 5009 1068 842 170 1187 235 8313 1282
NT 1183 344 4647 990 782 158 1101 218 7713 1189
Total 80 440 23 401 316 146 67 377 53 161 10 744 74 913 14800 524 661 80 915
Table 6. Total annual opportunity cost of pressure injury (PI; A$ million), by state and PI stage (2012–13)
NSW, New South Wales; Vic., Victoria; Qld, Queensland; WA, Western Australia; SA, South Australia; Tas., Tasmania; ACT, Australia Capitol Territory;
NT, Northern Territory
States Stage I Stage II Stage III Stage IV Total
Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
NSW 39.69 11.55 156.00 33.25 26.23 5.30 36.96 7.30 258.88 39.93
Vic. 28.33 8.24 111.35 23.73 18.72 3.78 26.38 5.21 184.78 28.50
Qld 25.63 7.46 100.72 21.47 16.94 3.42 23.87 4.72 167.15 25.78
WA 15.14 4.40 59.48 12.68 10.00 2.02 14.10 2.78 98.72 15.22
SA 9.17 2.67 36.04 7.68 6.06 1.22 8.54 1.69 59.81 9.22
Tas. 2.57 0.75 10.10 2.15 1.70 0.34 2.39 0.47 16.76 2.58
ACT 2.39 0.70 9.41 2.00 1.58 0.32 2.23 0.44 15.61 2.41
NT 2.74 0.80 10.76 2.29 1.81 0.37 2.55 0.50 17.85 2.75
Total 125.65 36.55 493.85 105.25 83.04 16.78 117.02 23.12 819.56 126.40
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life may be expected to be considerable. Finally, data collection
for PI in the long-term care setting (home and nursing home),
such as prevalence, outpatient visits, medications, social services
and informal care, should receive more funding attention. This
would enable future research to fully capture the cost of PI
outside the public hospital setting, which no doubt represents a
substantial additional economic burden for the health system
and for society as a whole.
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